{"schemaVersion":"WPF-PUBLIC-UPDATES-1.0","generatedAt":"2026-11-08T17:24:42.481Z","governance":"Only published governed records are included.","counts":{"evidence":50,"regulatory":25,"corrections":0},"evidence":[{"id":"31298496-4d67-4d8b-b02c-ba51617fd918","title":"Successful treatment with teduglutide for an adolescent with cerebral palsy accompanied by short bowel syndrome.","updatedAt":"2026-09-27T02:32:14.971Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1111/ped.15894","pubmedId":"40019443","peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"3af06bcf-ee02-4d7c-9391-a8a69a9c2a3b","title":"Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina.","updatedAt":"2026-09-27T02:32:14.899Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.4292/wjgpt.v16.i4.110642","pubmedId":"41378076","peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"2f65ea8b-0cc6-4558-8b50-78fafd13c83e","title":"Comment on \"real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure\".","updatedAt":"2026-09-27T02:32:14.826Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/j.clnesp.2026.105083","pubmedId":"42674361","peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"651af1df-53e3-4b61-bdd1-e2298322dfaf","title":"PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.","updatedAt":"2026-09-27T02:32:14.753Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1002/jpr3.70144","pubmedId":"42110144","peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"41e581e2-8fcd-49be-a7e0-ac8757b1a30e","title":"Teduglutide in Enterocolitis Secondary to Graft-Versus-Host Disease Post-Bone Transplant: Case Report","updatedAt":"2026-09-27T02:32:14.680Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.20944/preprints202602.1566.v1","pubmedId":null,"peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"48d7ba0d-51ed-48f3-adb0-1ec9b454e688","title":"Effectiveness and Safety of Teduglutide Treatment in Adult Patients with Short Bowel Syndrome: A Case Series and Review of Current Evidence.","updatedAt":"2026-09-27T02:32:14.607Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.3390/jcm15052033","pubmedId":"41827448","peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"d2cff5db-3f10-4ea6-ab7a-905d04143505","title":"Safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study. ","updatedAt":"2026-09-27T02:32:14.534Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1038/s41390-026-05489-0","pubmedId":"42754721","peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"3a3b07c5-fcc8-4d27-8d9b-fdd14df3b8e9","title":"Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome.","updatedAt":"2026-09-27T02:32:14.461Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.4292/wjgpt.v17.i1.117071","pubmedId":"41809219","peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"6c83c7be-b4e8-4524-931b-f36c982c79ab","title":"Add-on to current guidelines for monitoring of SBS patients treated with teduglutide","updatedAt":"2026-09-27T02:32:14.387Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1038/s44355-025-00047-7","pubmedId":null,"peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"881b5501-91f8-476e-a071-ad6f66ae6794","title":"Dextran Sulfate/Pramlintide Polyelectrolyte Nanoparticles as a Promising Delivery System: Optimization, Evaluation of Supramolecular Interactions and Effect on Conformational Stability of the Peptide Drug","updatedAt":"2026-09-27T02:32:13.589Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.21577/0103-5053.20210062","pubmedId":null,"peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"d638d53c-2eb8-4601-834b-98f960a824d5","title":"Ultra-fast insulin-pramlintide co-formulation for improved glucose management in diabetic rats","updatedAt":"2026-09-27T02:32:13.517Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1101/2021.04.12.439573","pubmedId":null,"peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"3f627d06-545c-4c0e-a414-042bd5694c28","title":"Slow post-induction specific growth rate enhances recombinant protein expression in Escherichia coli: Pramlintide multimer and ranibizumab production as case studies","updatedAt":"2026-09-27T02:32:13.442Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/j.procbio.2022.01.009","pubmedId":null,"peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"eeba8754-3d6d-48c7-891b-25e428211268","title":"Effect of Zn(II) on pramlintide: structural kink, fibril formation, antifungal activity","updatedAt":"2026-09-27T02:32:13.366Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.21203/rs.3.rs-1954176/v1","pubmedId":null,"peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"b2054d72-c05a-49a7-8ce9-528996a6a359","title":"Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles.","updatedAt":"2026-09-27T02:32:13.293Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.4103/1735-5362.359428","pubmedId":"36704426","peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"49cf5d00-68af-436a-ae24-9afb30dc9f64","title":"Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Systematic Review","updatedAt":"2026-09-27T02:32:13.219Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.3390/app122010262","pubmedId":null,"peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"c81113f5-2e62-46e9-b0a6-671b66aa1814","title":"Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide.","updatedAt":"2026-09-27T02:32:13.147Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.3390/pharmaceutics14030553","pubmedId":"35335929","peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"f2971575-b274-4a42-8781-d56f2b6789eb","title":"Linaclotide for Bowel Preparation: Is \"Afterload Reduction\" Not Just for Heart Failure Anymore?","updatedAt":"2026-09-27T02:32:13.074Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.14309/ajg.0000000000003375","pubmedId":"40110861","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"da3ce04f-b7ad-4cf9-9a5c-41a2ca677d94","title":"Polysaccharide-peptide complexes stabilized around nanoemulsion droplets: A new approach for nasal delivering of pramlintide and insulin","updatedAt":"2026-09-27T02:32:13.073Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/j.jddst.2023.104527","pubmedId":null,"peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"fb89c229-2722-48a5-9936-9fe68e8531e3","title":"Partially differentiated enterocytes in ileal and distal-colonic human F508del-CF-enteroids secrete fluid in response to forskolin and linaclotide","updatedAt":"2026-09-27T02:32:12.997Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1101/2025.02.03.636268","pubmedId":null,"peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"8854ff06-92f1-4d0b-b523-20c2b74cfaad","title":"QBD Approach for Design and Characterization of Pramlintide Microspheres for Controlled Drug Release","updatedAt":"2026-09-27T02:32:12.997Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1007/s12247-023-09795-6","pubmedId":null,"peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"0ddbd66b-e550-41a3-9628-a9156ff54540","title":"Beyond the injection: delivery systems reshaping retinal disease management.","updatedAt":"2026-09-27T02:32:12.942Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1080/14656566.2025.2496424","pubmedId":"40319468","peptide":{"slug":"elamipretide","commonName":"Elamipretide"}},{"id":"6e90c531-b25d-4cab-b738-31396b804950","title":"Oral delivery of the amylin receptor agonist pramlintide","updatedAt":"2026-09-27T02:32:12.925Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1101/2023.11.09.566408","pubmedId":null,"peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"fc5ed4ca-95a8-4d7a-a473-0707f8ea6b65","title":"A pharmacovigilance study of the association between linaclotide/plecanatide and muscle spasms based on food and drug administration adverse event reporting system.","updatedAt":"2026-09-27T02:32:12.924Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.3389/fphar.2025.1635792","pubmedId":"40843382","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"fe74c55f-e3cb-480b-823a-afffa3cacc3f","title":"Intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions improves cognitive impairments in a mouse model of Alzheimer's disease.","updatedAt":"2026-09-27T02:32:12.853Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/j.ijbiomac.2024.136158","pubmedId":"39362444","peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"e0c73c22-756e-4046-a1a6-c61c228f3cdf","title":"Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database.","updatedAt":"2026-09-27T02:32:12.850Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1080/14740338.2025.2519833","pubmedId":"40503810","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"4f2418eb-694e-4c62-a8a3-fefcdea1ca1f","title":"Correction to: Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK‑3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high‑fat dietstreptozocin rat model.","updatedAt":"2026-09-27T02:32:12.780Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1007/s00424-024-02959-4","pubmedId":"38575720","peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"b953a25b-a399-4b7b-8e28-474e5c91d060","title":"Clinical Study on the Application of Low-Dose 2L Lactulose Combined with Linaclotide in Bowel Preparation Before Colonoscopy","updatedAt":"2026-09-27T02:32:12.778Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.21203/rs.3.rs-7391900/v1","pubmedId":null,"peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"e72da68c-250d-4a13-8ee1-62aa37143632","title":"Efficacy of linaclotide as adjunct for bowel preparation in patients with chronic constipation: a pre-specified analysis of the APPLE trial.","updatedAt":"2026-09-27T02:32:12.705Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.5946/ce.2026.214","pubmedId":"42681900","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"f50e0560-ba9e-4a95-8160-3d5a0bbdffc3","title":"Efficacy and safety of Guanylyl cyclase C agonists (linaclotide and plecanatide) in patients with irritable bowel syndrome with constipation: a systematic review and meta-analysis of randomized controlled trials.","updatedAt":"2026-09-27T02:32:12.630Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.3389/fphar.2026.1761301","pubmedId":"42038325","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"0bb313f1-7398-457b-bf77-a06f1236b762","title":"Efficacy and safety of linaclotide plus polyethylene glycol for bowel preparation before colonoscopy in elderly Chinese patients: a systematic review and meta-analysis.","updatedAt":"2026-09-27T02:32:12.558Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.3389/fmed.2026.1833539","pubmedId":"42482900","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"99948996-2bf8-4977-ac0f-1cdc56728841","title":"Efficacy of Polyethylene Glycol Electrolyte Powder Combined with Linaclotide for Bowel Preparation for Colonoscopy in Children with Functional Constipation.","updatedAt":"2026-09-27T02:32:12.485Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1620/tjem.2026.j007","pubmedId":"41780967","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"03fb57e7-3eb0-4735-adf1-9f73506aad54","title":"Application of oral sulfate solution combined with linaclotide in bowel preparation for colonoscopy.","updatedAt":"2026-09-27T02:32:12.411Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.3389/fmed.2026.1696298","pubmedId":"41889509","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"a3300473-b565-4b50-afe9-442ebf497d4d","title":"Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial","updatedAt":"2026-09-27T02:32:11.813Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/s0168-8278(22)00570-0","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"b5e1e1c4-3f4b-4297-9334-0cdc4dc4f1b3","title":"Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators","updatedAt":"2026-09-27T02:32:11.743Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1161/circ.146.suppl_1.13440","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"86457df2-fd09-400c-b05b-8a9624688213","title":"334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity","updatedAt":"2026-09-27T02:32:11.673Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.2337/db22-334-or","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"7016886e-4b9e-4bc5-bc3c-16bd79b8e62b","title":"Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial","updatedAt":"2026-09-27T02:32:11.603Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/s0168-8278(23)00517-2","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"efc80dc8-998f-4a98-8747-8cab2df2b845","title":"WED-251 Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis","updatedAt":"2026-09-27T02:32:11.532Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/s0168-8278(24)01588-5","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"0a875d60-b5d4-45bb-8ce3-19efcdef5fcb","title":"WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial","updatedAt":"2026-09-27T02:32:11.460Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/s0168-8278(24)01555-1","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"50d23c8c-8641-471a-925b-70d55af30321","title":"262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial","updatedAt":"2026-09-27T02:32:11.390Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.2337/db24-262-or","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"2eaf78ff-58cd-4f15-baf6-278d3c6fa6c8","title":"WED-219 Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model","updatedAt":"2026-09-27T02:32:11.320Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/s0168-8278(24)01560-5","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"c98ec9fe-f287-417d-bb9c-385e2518c43c","title":"Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials","updatedAt":"2026-09-27T02:32:11.250Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.64898/2025.12.22.25342824","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"421cf697-2b34-46e5-be3d-bd95d5e27ad8","title":"749-P: Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment","updatedAt":"2026-09-27T02:32:11.180Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.2337/db25-749-p","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"8dd1478a-69ef-4493-96b1-a840c0256811","title":"SAT-453 MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)","updatedAt":"2026-09-27T02:32:11.109Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/s0168-8278(25)01709-x","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"8fd90a08-4cfc-4d6e-9853-095c65e3db15","title":"778-P: Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model","updatedAt":"2026-09-27T02:32:11.040Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.2337/db25-778-p","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"53eb521a-a35e-4d75-aea3-3f56b8c3f62f","title":"228-OR: Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight","updatedAt":"2026-09-27T02:32:10.957Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.2337/db25-228-or","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"85a98c57-9e5a-4b05-890f-a6159a610726","title":"Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men.","updatedAt":"2026-09-27T02:32:10.895Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1007/s42000-026-00795-y","pubmedId":"42230485","peptide":{"slug":"kisspeptin","commonName":"Kisspeptin"}},{"id":"1132cdba-1775-4ed9-b3f1-535da8fc28a2","title":"748-P: Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide","updatedAt":"2026-09-27T02:32:10.887Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.2337/db25-748-p","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"f14a330a-e1ca-4df5-839e-929b4ab739eb","title":"Naringenin protects against renal ischemia-reperfusion injury following unilateral nephrectomy via modulation of oxidative stress and kisspeptin expression.","updatedAt":"2026-09-27T02:32:10.823Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1007/s11255-026-05293-z","pubmedId":"42490039","peptide":{"slug":"kisspeptin","commonName":"Kisspeptin"}},{"id":"1054c758-2ea4-4e5e-bdb4-3a0f5c03be7c","title":"Cryo-EM structure of afamelanotide-MC4R-Gs_Nb35 complex","updatedAt":"2026-09-27T02:32:10.820Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.2210/pdb7f54/pdb","pubmedId":null,"peptide":{"slug":"afamelanotide","commonName":"Afamelanotide"}},{"id":"4027ffb9-1b52-45fc-9f1c-5a517ebc619d","title":"OS-016 Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis","updatedAt":"2026-09-27T02:32:10.817Z","publicationYear":null,"evidenceTier":"insufficient","doi":"10.1016/s0168-8278(26)00326-0","pubmedId":null,"peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}}],"regulatory":[{"id":"7f464d98-fe8f-430d-84dd-4197eda703dd","jurisdiction":"United States — FDA","status":"not_approved","updatedAt":"2026-09-23T23:29:36.671Z","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","peptide":{"slug":"thymosin-beta-4","commonName":"Thymosin beta-4"}},{"id":"00bf38d2-42c0-4a79-82f7-e25ff0a7e339","jurisdiction":"European Union — EMA","status":"not_approved","updatedAt":"2026-09-23T23:29:36.671Z","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"thymosin-beta-4","commonName":"Thymosin beta-4"}},{"id":"9462f73a-f08f-4d6a-bfca-e8d7bfef02ff","jurisdiction":"European Union — EMA","status":"not_approved","updatedAt":"2026-09-23T23:29:35.429Z","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"1b174f1d-2079-4f36-8646-b63185b66adb","jurisdiction":"United States — FDA","status":"approved","updatedAt":"2026-09-23T23:29:35.429Z","sourceTitle":"FDA SYMLIN (pramlintide acetate) prescribing information","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021332s025lbl.pdf","peptide":{"slug":"pramlintide","commonName":"Pramlintide"}},{"id":"e81499ee-f1da-4570-beaa-78087a433012","jurisdiction":"European Union — EMA","status":"not_approved","updatedAt":"2026-09-23T23:29:34.166Z","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"368e5069-d525-46ce-bb1f-51374694020d","jurisdiction":"United States — FDA","status":"not_approved","updatedAt":"2026-09-23T23:29:34.166Z","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","peptide":{"slug":"pemvidutide","commonName":"Pemvidutide"}},{"id":"98e379e0-c41d-469d-8870-2bb62d3562ea","jurisdiction":"China — NMPA","status":"approved","updatedAt":"2026-09-23T23:29:32.990Z","sourceTitle":"Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management","sourceUrl":"https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html","peptide":{"slug":"mazdutide","commonName":"Mazdutide"}},{"id":"b82b29e5-6b0e-4718-a3c0-3d7697690157","jurisdiction":"United States — FDA","status":"not_approved","updatedAt":"2026-09-23T23:29:32.990Z","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","peptide":{"slug":"mazdutide","commonName":"Mazdutide"}},{"id":"1e365c04-7dd1-44df-9094-8d930872a3bf","jurisdiction":"European Union — EMA","status":"approved","updatedAt":"2026-09-23T23:29:31.762Z","sourceTitle":"European Medicines Agency: Baqsimi (glucagon)","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/baqsimi","peptide":{"slug":"glucagon","commonName":"Glucagon"}},{"id":"47960744-793a-4a7a-af94-d83149a998be","jurisdiction":"United States — FDA","status":"approved","updatedAt":"2026-09-23T23:29:31.762Z","sourceTitle":"FDA GlucaGen (glucagon) prescribing information","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020918s054lbl.pdf","peptide":{"slug":"glucagon","commonName":"Glucagon"}},{"id":"8e7b2ee3-5ed3-418a-b937-069649b0b80b","jurisdiction":"European Union — EMA","status":"not_approved","updatedAt":"2026-09-23T23:29:30.479Z","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"humanin","commonName":"Humanin"}},{"id":"721a0587-b36b-440b-952b-5c6ff04d2cba","jurisdiction":"United States — FDA","status":"not_approved","updatedAt":"2026-09-23T23:29:30.479Z","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","peptide":{"slug":"humanin","commonName":"Humanin"}},{"id":"53cbba17-290e-4b3f-a6a3-d6c6f12a34b8","jurisdiction":"European Union — EMA","status":"not_approved","updatedAt":"2026-09-23T23:29:29.220Z","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"cagrilintide","commonName":"Cagrilintide"}},{"id":"27e5d727-b171-48cd-b4c2-a5c703b871e9","jurisdiction":"United States — FDA","status":"not_approved","updatedAt":"2026-09-23T23:29:29.220Z","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","peptide":{"slug":"cagrilintide","commonName":"Cagrilintide"}},{"id":"a9667ef7-173b-45fd-b8ea-944a9678a318","jurisdiction":"European Union — EMA","status":"approved","updatedAt":"2026-09-23T23:29:27.991Z","sourceTitle":"European Medicines Agency: Prialt (ziconotide)","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/prialt","peptide":{"slug":"ziconotide","commonName":"Ziconotide"}},{"id":"f797e8d2-c205-4ac8-94c4-f6c27022e863","jurisdiction":"United States — FDA","status":"approved","updatedAt":"2026-09-23T23:29:27.991Z","sourceTitle":"FDA PRIALT (ziconotide) prescribing information","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021060s003lbl.pdf","peptide":{"slug":"ziconotide","commonName":"Ziconotide"}},{"id":"aa739181-10f8-4aa1-a7af-13c6931ef661","jurisdiction":"European Union — EMA","status":"approved","updatedAt":"2026-09-23T23:29:26.743Z","sourceTitle":"European Medicines Agency: Revestive (teduglutide)","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/revestive","peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"a5dea127-3a97-453a-bf8c-343317bcdfa5","jurisdiction":"United States — FDA","status":"approved","updatedAt":"2026-09-23T23:29:26.743Z","sourceTitle":"FDA GATTEX (teduglutide) prescribing information","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203441s022lbl.pdf","peptide":{"slug":"teduglutide","commonName":"Teduglutide"}},{"id":"d41e0d0f-b670-49f5-a3be-e1a90f7edec8","jurisdiction":"European Union — EMA","status":"approved","updatedAt":"2026-09-23T23:29:25.447Z","sourceTitle":"European Medicines Agency: Constella (linaclotide)","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/constella","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"d34e974e-7196-4a68-b878-89935e91e14e","jurisdiction":"United States — FDA","status":"approved","updatedAt":"2026-09-23T23:29:25.447Z","sourceTitle":"FDA LINZESS (linaclotide) prescribing information","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202811s022lbl.pdf","peptide":{"slug":"linaclotide","commonName":"Linaclotide"}},{"id":"0cc95154-75db-496c-b717-50c791f0fd12","jurisdiction":"United States — FDA","status":"not_approved","updatedAt":"2026-09-23T23:29:23.900Z","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","peptide":{"slug":"kisspeptin","commonName":"Kisspeptin"}},{"id":"71d8a989-fd70-4fec-81fd-34e2bd21508d","jurisdiction":"European Union — EMA","status":"not_approved","updatedAt":"2026-09-23T23:29:23.900Z","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"kisspeptin","commonName":"Kisspeptin"}},{"id":"35978346-76a0-48cd-9416-5da6f59bc6cf","jurisdiction":"United States — FDA","status":"approved","updatedAt":"2026-09-23T23:29:22.653Z","sourceTitle":"FDA VYLEESI (bremelanotide injection) prescribing information","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf","peptide":{"slug":"bremelanotide","commonName":"Bremelanotide"}},{"id":"c29f5165-0311-4f06-8bec-418a96ee40e8","jurisdiction":"European Union — EMA","status":"not_approved","updatedAt":"2026-09-23T23:29:22.653Z","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"bremelanotide","commonName":"Bremelanotide"}},{"id":"c8730324-23d5-417e-af3c-6aad11e3beea","jurisdiction":"United States — FDA","status":"approved","updatedAt":"2026-09-23T23:29:20.694Z","sourceTitle":"FDA Orphan Drug Designations and Approvals: afamelanotide / SCENESSE","sourceUrl":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208","peptide":{"slug":"afamelanotide","commonName":"Afamelanotide"}}],"corrections":[]}